Healios K.K. (HLOSF)

Market Cap	262.37M
Revenue (ttm)	3.93M
Net Income (ttm)	-29.20M
Shares Out	n/a
EPS (ttm)	-0.32
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	288
Average Volume	3,185
Open	2.250
Previous Close	2.000
Day's Range	2.250 - 2.250
52-Week Range	0.926 - 2.420
Beta	1.26
RSI	62.45
Earnings Date	May 13, 2025

About Healios K.K.

Healios K.K. engages in the research and development, manufacture, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company develops HLCM051, which is preparing for phase 3 clinical trial, as well as preparing for approval for the treatment of acute respiratory distress syndrome; HLCM051, which is in phase 2/3 and phase 3 clinical trial to treat ischemic stroke; and HLCM051, which is in phase 2 clinical trial to treat trauma. It also develops HLCR011, which is in phase 1/2 clinical trial f...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 65
• Stock Exchange: OTCMKTS
• Ticker Symbol: HLOSF

Financial Performance

In 2024, Healios K.K.'s revenue was 560.00 million, an increase of 362.81% compared to the previous year's 121.00 million. Losses were -4.24 billion, 10.8% more than in 2023.

Financial numbers in JPY